£500,000 grant to support precision antibiotics for cystic fibrosis

Glox Therapeutics has been awarded up to £500,000 from the £3 million Collaborative Discovery Programme (CDP), funded by LifeArc through the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. The grant will support the development of precision antibiotics to combat antimicrobial-resistant lung infections in cystic fibrosis (CF) patients.

CF, affecting over 162,000 people worldwide, leads to chronic lung infections due to pathogens like Pseudomonas aeruginosa. Over time, these infections can develop resistance to conventional antibiotics, creating a pressing need for effective new treatments.

Glox’s novel bacteriocin-based platform offers precision antibiotics that target resistant bacteria without harming the human microbiome, providing a potential solution to CF-associated infections.

The CDP, led by Medicines Discovery Catapult, LifeArc, and Cystic Fibrosis Trust, promotes collaboration across industry, academia, and healthcare to drive CF antimicrobial research forward. The funding will allow Glox to use this cross-sector expertise to accelerate its drug development.

Dr James Clark, CEO of Glox Therapeutics, said: "This funding and collaboration are critical to advancing our unique antibiotics to tackle AMR in CF, addressing an urgent unmet need."

Dr Catherine Kettleborough, LifeArc, added: "Collaboration is key in overcoming AMR challenges, and we’re excited to support Glox in this important work."

Dr Beverley Isherwood, Medicines Discovery Catapult, and Dr Paula Sommer, Cystic Fibrosis Trust, emphasised the importance of this initiative in developing new treatments to combat the damaging effects of CF lung infections.

More information online